Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID.

The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines, like TNX-1800, offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines.

This choice of TNX-1800 is a testament to Tonix's nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics.

This development highlights the significance of vaccine platforms for tackling various infectious threats. Tonix's approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform's adaptability positions it as a valuable tool for future vaccine strategies.

Contact Details

Proactive Studio

+1 347-449-0879

na-editorial@proactiveinvestors.com